


GLOBAL REPORT

	No of participants	No of responded participants	Response percentage
Bordetella pertussis, antibodies, November, 4-2023	64	59	92.2 %


Summary



Summary	AVR success rate
Sample S001	82.1 %
Sample S002	88.3 %
Average:	85.2 %


Sample S001

Sample S001 success rate




Sample S001 results	Responded	AVR success rate	Count
	Clinical interpretation	93 %	62
	BopeAbA	61.5 %	39
	BopeAbG	85 %	60
	BopeAbM	62.5 %	16
	Total:	82.1 %	177

Sample S001 Clinical interpretation




Clinical interpretation	Interpretation	Interpretation count	AVR success rate	Interpretation Score
	Positive, sign of infection	31	100 %	4
	Uncertain result	2	0 %	0
	Negative, no sign of infection	1	0 %	0
	Longstanding infection, serological scar	9	100 %	4
	Laboratory does not give clinical interpretations	19	-	-
	Total:	62	93 %	


Sample S001 BopeAbA



Sample S001 BopeAbG



Sample S001 BopeAbM



Legend for BopeAbA: Negative (Blue), Borderline (Orange), Positive (Green)

Legend for BopeAbG: Negative (Blue), Borderline (Orange), Weak positive (Green), Positive (Light Green)

Legend for BopeAbM: Negative (Blue), Weak positive (Green), Positive (Light Green)

BopeAbA	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Negative		24		100 %	2
		Diasorin LIAISON® Bordetella pertussis Toxin IgA		6		
		Euroimmun Anti- B. pertussis Toxin ELISA IgA		9		
		Euroimmun Anti-Bordetella FHA ELISA IgA		2		
		Novagnost Bordetella pertussis toxin (PT) IgA		1		
		Novatec NovaLisa B. pertussis IgA ELISA		1		
		Orgentec B. pertussis TOXIN IgA ELISA		2		
		TestLine BLOT-LINE Bordetella IgA		1		
		TestLine Microblot-Array Bordetella IgA		1		
		Virion/Serion B. pertussis IgA		1		
	Borderline		3		0 %	0
		TestLine BLOT-LINE Bordetella IgA		1		
		TestLine EIA Bordetella pertussis Toxin IgA		1		
		Virotech Bordetella pertussis IgA ELISA		1		
	Positive		12		0 %	0
		Diasorin LIAISON® Bordetella pertussis Toxin IgA		5		
		Euroimmun Anti- B. pertussis Toxin ELISA IgA		1		
		Euroimmun Anti-Bordetella FHA ELISA IgA		1		
		Novatec NovaLisa B. pertussis IgA ELISA		1		
		Orgentec B. pertussis TOXIN IgA ELISA		2		
		Siemens Novagnost B. pertussis IgA		2		
	Total:		39		61.5 %	


BopeAbG	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Negative		1		0 %	0
		Euroimmun Anti-B. pertussis Toxin ELISA IgG		1		
	Borderline		6		0 %	0
		Euroimmun Anti-B. pertussis Toxin ELISA IgG		1		
		Euroimmun Anti-Bordetella FHA ELISA IgG		1		
		Novatec NovaLisa B. pertussis IgG ELISA		1		
		Vircell VIRCLIA Monotest Bordetella Pertussis Toxin IgG		1		
		Virion/Serion B. pertussis Toxin IgG		2		
	Weak positive		2		0 %	0
		Euroimmun Anti-B. pertussis Toxin ELISA IgG		2		
	Positive		51		100 %	2
		Diasorin LIAISON® Bordetella pertussis Toxin IgG		19		
		Euroimmun Anti-B. pertussis Toxin ELISA IgG		10		
		Euroimmun Anti-Bordetella FHA ELISA IgG		3		
		Euroimmun Euroline Bordetella pertussis IgG		1		
		Novagnost Bordetella pertussis toxin (PT) IgG		1		

	Novatec NovaLisa B. pertussis IgG ELISA		2		
	Orgentec B. pertussis TOXIN IgG ELISA		5		
	Siemens Novagnost B. pertussis IgG		1		
	TestLine BLOT-LINE Bordetella IgG		1		
	TestLine EIA Bordetella pertussis Toxin IgG		1		
	TestLine Microblot-Array Bordetella IgG		1		
	TestLine SmartEIA Bordetella pertussis Toxin IgG		1		
	Viricell VIRCLIA Monotest Bordetella Pertussis Toxin IgG		2		
	Virion/Serion B. pertussis IgG		2		
	Virotech Bordetella pertussis IgG ELISA		1		
	Total:		60		85 %

BopeAbM	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Negative		6		0 %	0
		Euroimmun Anti-B. pertussis ELISA IgM		2		
		Novatec NovaLisa B. pertussis IgM ELISA		1		
		TestLine BLOT-LINE Bordetella IgM		1		
		TestLine Microblot-Array Bordetella IgM		1		
		Virion/Serion B. pertussis IgM		1		
	Weak positive		1		100 %	2
		Euroimmun Anti-B. pertussis ELISA IgM		1		
	Positive		9		100 %	2
		Euroimmun Anti-B. pertussis ELISA IgM		5		
		Novatec NovaLisa B. pertussis IgM ELISA		2		
		Siemens Novagnost B. pertussis IgM		2		
	Total:		16		62.5 %	


Sample S002

Sample S002 success rate



Sample S002 results	Responded	AVR success rate	Count
	Clinical interpretation	85.7 %	62
	BopeAbA	97.4 %	39
	BopeAbG	85 %	60
	BopeAbM	94.1 %	17
	Total:	88.3 %	178


Sample S002 Clinical interpretation



- Positive, sign of infection
- Uncertain result
- Negative, no sign of infection
- Longstanding infection, serological scar
- Laboratory does not give clinical interpretations


Clinical interpretation	Interpretation	Interpretation count	AVR success rate	Interpretation Score
	Positive, sign of infection	5	0 %	0
	Uncertain result	1	0 %	0
	Negative, no sign of infection	42	100 %	4
	Longstanding infection, serological scar	1	0 %	0
	Laboratory does not give clinical interpretations	13	-	-
	Total:	62	85.7 %	

Sample S002 BopeAbA




■ Negative ■ Positive

Sample S002 BopeAbG



■ Negative ■ Weak positive ■ Positive

Sample S002 BopeAbM



■ Negative ■ Borderline

BopeAbA	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Negative		38		100 %	2
		Diasorin LIAISON® Bordetella pertussis Toxin IgA		11		
		Euroimmun Anti- B. pertussis Toxin ELISA IgA		10		
		Euroimmun Anti-Bordetella FHA ELISA IgA		2		
		Novagnost Bordetella pertussis toxin (PT) IgA		1		
		Novatec NovaLisa B. pertussis IgA ELISA		2		
		Orgentec B. pertussis TOXIN IgA ELISA		4		
		Siemens Novagnost B. pertussis IgA		2		
		TestLine BLOT-LINE Bordetella IgA		1		
		TestLine EIA Bordetella pertussis Toxin IgA		1		
		TestLine Microblot-Array Bordetella IgA		1		
		TestLine SmartEIA Bordetella pertussis Toxin IgA		1		
		Virion/Serion B. pertussis IgA		1		
		Virotech Bordetella pertussis IgA ELISA		1		
	Positive		1		0 %	0
		Euroimmun Anti-Bordetella FHA ELISA IgA		1		
	Total:		39		97.4 %	

BopeAbG	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Negative		51		100 %	2
		Diasorin LIAISON® Bordetella pertussis Toxin IgG		19		
		Euroimmun Anti-B. pertussis Toxin ELISA IgG		13		
		Euroimmun Anti-Bordetella FHA ELISA IgG		2		
		Novagnost Bordetella pertussis toxin (PT) IgG		1		
		Novatec NovaLisa B. pertussis IgG ELISA		2		
		Orgentec B. pertussis TOXIN IgG ELISA		5		
		Siemens Novagnost B. pertussis IgG		1		
		TestLine EIA Bordetella pertussis Toxin IgG		1		
		TestLine SmartEIA Bordetella pertussis Toxin IgG		1		
		Viricell VIRCLIA Monotest Bordetella Pertussis Toxin IgG		3		
		Virion/Serion B. pertussis IgG		1		
		Virion/Serion B. pertussis Toxin IgG		2		
	Weak positive		2		0 %	0
		Euroimmun Euroline Bordetella pertussis IgG		1		
		Virion/Serion B. pertussis IgG		1		
	Positive		7		0 %	0
		Euroimmun Anti-B. pertussis Toxin ELISA IgG		2		
		Euroimmun Anti-Bordetella FHA ELISA IgG		1		
		Novatec NovaLisa B. pertussis IgG ELISA		1		
		TestLine BLOT-LINE Bordetella IgG		1		

		TestLine Microblot-Array Bordetella IgG		1		
		Virotech Bordetella pertussis IgG ELISA		1		
	Total:		60		85 %	

BopeAbM	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Negative		16		100 %	2
		Euroimmun Anti-B. pertussis ELISA IgM		8		
		Novatec NovaLisa B. pertussis IgM ELISA		3		
		Siemens Novagnost B. pertussis IgM		2		
		TestLine BLOT-LINE Bordetella IgM		1		
		TestLine Microblot-Array Bordetella IgM		1		
		Virion/Serion B. pertussis IgM		1		
	Borderline		1		0 %	0
		Euroimmun Anti-B. pertussis ELISA IgM		1		
	Total:		17		94.1 %	

Report Info

PARTICIPANTS

Altogether 64 laboratories from 19 countries participated in this EQA round.

REPORT INFO

The results are divided into groups according to the method stated by the laboratory and presented in laboratory-specific tables. Accepted results are marked with green color and laboratory's own result with a black radio button . In the scoring report you will find summaries of overall success rate and sample specific success rates (%). Sample specific interpretations are shown in pie diagrams as percentages and the total interpretation and methodic counts in the tables. If you have not reported any results you will get a note: "You have not responded in time, only global report is available."

For information on report interpretation and performance evaluation, please see the "EQAS Interpretation guidelines" in LabScala User instructions. In case you have any questions regarding the reports, please contact the EQA Coordinator.

SCORING

The round is scored based on test results and clinical interpretations when 60% or more of the participants report the expected result and when at least three results are reported.

The following general rules are applied:

Correct/expected test result 2/2 points
False/deviating test result 0/2 points
Correct/expected clinical interpretation 4/4 points
False/deviating clinical interpretation 0/4 points

The performance of the laboratory is assessed by the Own success rate (%). The target is 100%. The examination-specific scores obtained by the laboratory in the round are converted to Own success rate per sample (scores/maximum scores*100). The Laboratory's Own success rate is the average of the sample success rates.

The success rate for the entire round (AVR success rate) is calculated from the total number of scores given to the results per sample (all scores/maximum scores*100). The AVG success rate of the entire round is the average of the sample success rates. The difference in the Laboratory's Own success rate (%) to the corresponding numbers for the entire round is shown in the table.